Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Cervical Cancer | Primary research

Enhanced expression of microtubule-associated protein 7 functioned as a contributor to cervical cancer cell migration and is predictive of adverse prognosis

Authors: Ning Tang, Dan Lyu, Jian-Fang Chang, Zhi-Tao Liu, Yan Zhang, Hai-Ping Liu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Cervical cancer (CC) is one of the most common female malignancies over the world. Microtubule-associated protein 7 (MAP7) belongs to the family of microtubule-associated proteins (MAPs) which involve in microtubule dynamics and are critical in several important cellular and intracellular activities. This study aimed to investigate the expression and potential role of MAP7 in CC.

Methods

The expression level of MAP7 in CC tissues and normal tissues were analyzed using the data obtained from The cancer genomes atlas (TCGA) and genotype-tissue expression (GTEx) databases. The prognostic value of MAP7 in patients with CC was analyzed by Kaplan–Meier analysis, Univariate and Multivariate analyses. Moreover, the influences of MAP7 expression alteration on the viability and motility of Caski, HeLa and C-33A cells was measured by CCK8 assay, colony formation assay, scratch assay, and transwell migration and invasion assays. Flow cytometry was conducted to determine cell apoptosis. Western blot was performed to evaluate the impact of MAP7 on the expression of apoptotic-related proteins as well as mitogen-activated protein kinase (MAPK) signaling pathway-related proteins. In vivo tumorigenicity assay was performed to explore the influence of MAP7 on tumor growth.

Results

Up-regulation of MAP7 was observed in CC tissues and high MAP7 expression was positively correlated with worse prognosis. Multivariate analyses suggested that MAP7 expression can be served as an independent predictor for overall survival of patients with CC. Knockdown of MAP7 markedly suppressed Caski and HeLa cell viability, migration and invasion while notably induced cell apoptosis. Furthermore, depletion of MAP7 in Caski and HeLa cells elevated the expression levels of Active-caspase 3 and Bax, but declined the level of Bcl-2. Whilst, overexpression of MAP7 in C-33A cells presented the opposite outcomes. Additionally, knockdown of MAP7 significantly decreased the phosphorylation of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in Caski and HeLa cells, and overexpression of MAP7 increased their phosphorylation in C-33A cells, indicating that MAP7 may regulate the MAPK signaling pathway in CC cells. In vivo assays revealed that knockdown of MAP7 remarkably repressed the growth of CC tumors.

Conclusion

The results of the present study suggest that MAP7 functions as a promoter during the occurrence and progression of CC, and that MAP7 may serve as a promising therapeutic target in CC.
Literature
1.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
2.
go back to reference Ferlay JB, et al. Cancer incidence, mortality and prevalence worldwide. Lyon: GLOBOCAN; 2004. Ferlay JB, et al. Cancer incidence, mortality and prevalence worldwide. Lyon: GLOBOCAN; 2004.
3.
go back to reference Boyle P. Levin B world cancer report 2008. Geneva: World Health Organization; 2009. Boyle P. Levin B world cancer report 2008. Geneva: World Health Organization; 2009.
4.
go back to reference Koç Z, et al. The impact of education about cervical cancer and human papillomavirus on women’s healthy lifestyle behaviors and beliefs: using the PRECEDE educational model. Cancer Nurs. 2018;42(2):106–18.CrossRef Koç Z, et al. The impact of education about cervical cancer and human papillomavirus on women’s healthy lifestyle behaviors and beliefs: using the PRECEDE educational model. Cancer Nurs. 2018;42(2):106–18.CrossRef
5.
go back to reference Zanetta G, et al. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol. 2000;27:23–7.PubMed Zanetta G, et al. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol. 2000;27:23–7.PubMed
6.
go back to reference Yan W, et al. SirT1 mediates hyperbaric oxygen preconditioning-induced ischemic tolerance in rat brain. J Cereb Blood Flow Metab. 2013;33:396.CrossRef Yan W, et al. SirT1 mediates hyperbaric oxygen preconditioning-induced ischemic tolerance in rat brain. J Cereb Blood Flow Metab. 2013;33:396.CrossRef
7.
go back to reference Stumm R, et al. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem. 2007;103:1666–81.CrossRef Stumm R, et al. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem. 2007;103:1666–81.CrossRef
8.
go back to reference Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13:2849.CrossRef Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13:2849.CrossRef
9.
go back to reference Vanier MT, et al. Expression and distribution of distinct variants of E-MAP-115 during proliferation and differentiation of human intestinal epithelial cells. Cell Motil Cytoskeleton. 2003;55:221–31.CrossRef Vanier MT, et al. Expression and distribution of distinct variants of E-MAP-115 during proliferation and differentiation of human intestinal epithelial cells. Cell Motil Cytoskeleton. 2003;55:221–31.CrossRef
10.
go back to reference Sood R, et al. Cloning and characterization of an inversion breakpoint at 6q23.3 suggests a role for Map7 in sacral dysgenesis. Cytogenetic Genome Res. 2012;106:61–7.CrossRef Sood R, et al. Cloning and characterization of an inversion breakpoint at 6q23.3 suggests a role for Map7 in sacral dysgenesis. Cytogenetic Genome Res. 2012;106:61–7.CrossRef
11.
go back to reference Fu L, et al. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep. 2016;6:34546.CrossRef Fu L, et al. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep. 2016;6:34546.CrossRef
12.
go back to reference Blum C, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. 2008;33:579–84.PubMedPubMedCentral Blum C, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. 2008;33:579–84.PubMedPubMedCentral
13.
go back to reference Yan X, et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer. 2013;12:1–11.CrossRef Yan X, et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer. 2013;12:1–11.CrossRef
14.
go back to reference Wang H, et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011;32:1033.CrossRef Wang H, et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011;32:1033.CrossRef
15.
go back to reference Xin T, et al. PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407. Cell Death Dis. 2017;8:e2686.CrossRef Xin T, et al. PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407. Cell Death Dis. 2017;8:e2686.CrossRef
16.
go back to reference Zou C, et al. Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin beta1, FAK, and ERK pathways. Cell Biochem Biophys. 2013;65:455–62.CrossRef Zou C, et al. Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin beta1, FAK, and ERK pathways. Cell Biochem Biophys. 2013;65:455–62.CrossRef
17.
go back to reference Yang M. Huang CZ Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 2015;21:11673–9.CrossRef Yang M. Huang CZ Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 2015;21:11673–9.CrossRef
18.
go back to reference Shin SS, et al. MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling, cell cycle regulators, and Ets-1-mediated MMP-2 expression. Oncol Rep. 2016;36:2421–9.CrossRef Shin SS, et al. MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling, cell cycle regulators, and Ets-1-mediated MMP-2 expression. Oncol Rep. 2016;36:2421–9.CrossRef
19.
go back to reference Masson D. Kreis TE binding of E-MAP-115 to microtubules is regulated by cell cycle-dependent phosphorylation. J Cell Biol. 1995;131:1015–24.CrossRef Masson D. Kreis TE binding of E-MAP-115 to microtubules is regulated by cell cycle-dependent phosphorylation. J Cell Biol. 1995;131:1015–24.CrossRef
20.
go back to reference Ferguson SE, et al. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 2004;92:719–25.CrossRef Ferguson SE, et al. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 2004;92:719–25.CrossRef
21.
go back to reference Imada K, et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res. 2013;19:4638–50.CrossRef Imada K, et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res. 2013;19:4638–50.CrossRef
22.
go back to reference Huang B, et al. PKCepsilon inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett. 2016;376:148–54.CrossRef Huang B, et al. PKCepsilon inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett. 2016;376:148–54.CrossRef
23.
go back to reference Hu X, et al. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer. Cancer Lett. 2017;397:83–93.CrossRef Hu X, et al. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer. Cancer Lett. 2017;397:83–93.CrossRef
24.
go back to reference Kim EK. Choi EJ Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89:867–82.CrossRef Kim EK. Choi EJ Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89:867–82.CrossRef
25.
go back to reference Dk M, et al. MEK inhibitors in oncology: a patent review (2015-Present). Expert Opin Ther Pat. 2017;27:887–906.CrossRef Dk M, et al. MEK inhibitors in oncology: a patent review (2015-Present). Expert Opin Ther Pat. 2017;27:887–906.CrossRef
26.
go back to reference Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.CrossRef Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.CrossRef
27.
go back to reference Chakraborti S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.CrossRef Chakraborti S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.CrossRef
28.
go back to reference Balmanno K. Cook SJ Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:368–77.CrossRef Balmanno K. Cook SJ Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:368–77.CrossRef
29.
go back to reference Bai L, et al. ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins. Med Oncol. 2015;32:57.CrossRef Bai L, et al. ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins. Med Oncol. 2015;32:57.CrossRef
30.
go back to reference Kikuchi K, et al. Map7/7D1 and Dvl form a feedback loop that facilitates microtubule remodeling and Wnt5a signaling. EMBO Rep. 2018;19:e45471.CrossRef Kikuchi K, et al. Map7/7D1 and Dvl form a feedback loop that facilitates microtubule remodeling and Wnt5a signaling. EMBO Rep. 2018;19:e45471.CrossRef
Metadata
Title
Enhanced expression of microtubule-associated protein 7 functioned as a contributor to cervical cancer cell migration and is predictive of adverse prognosis
Authors
Ning Tang
Dan Lyu
Jian-Fang Chang
Zhi-Tao Liu
Yan Zhang
Hai-Ping Liu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01446-x

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine